SWEDISH ORPHAN BIOVITRUM
🇫🇷France
Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa
- First Posted Date
- 2024-12-04
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Swedish Orphan Biovitrum
- Target Recruit Count
- 78
- Registration Number
- NCT06716814
- Locations
- 🇪🇸
Sobi Investigational Site, Zaragoza, Spain
A Study to Evaluate Efficacy and Safety of Anakinra in Chinese Patients With Colchicine-resistent FMF
- First Posted Date
- 2024-10-30
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Swedish Orphan Biovitrum
- Target Recruit Count
- 3
- Registration Number
- NCT06666335
Pharmacokinetic Comparison of Efanesoctocog Alfa vs Other EHL-rFVIII Products in Participants With Severe Haemophilia A
- First Posted Date
- 2024-08-30
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Swedish Orphan Biovitrum
- Target Recruit Count
- 24
- Registration Number
- NCT06579144
- Locations
- 🇩🇪
Sobi Investigational site, Frankfurt, Germany
🇪🇸Sobi Investigational Site, Zaragoza, Spain
Assessment of Macrophage Activation syndromE in STill's Disease
- First Posted Date
- 2024-05-08
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Swedish Orphan Biovitrum
- Target Recruit Count
- 75
- Registration Number
- NCT06405152
- Locations
- 🇪🇸
Swedish Orphan Biovitrum Research Site, Barcelona, Spain
A Non-interventional, Post-Marketing Study to Describe Outcome of Nitisinone Treatment in HT-1 Patients
- First Posted Date
- 2024-01-26
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- Swedish Orphan Biovitrum
- Target Recruit Count
- 15
- Registration Number
- NCT06227429
- Locations
- 🇨🇳
Swedish Orphan Biovitrum Research Site, Wuhan, China
Evaluation of IFNγ and Inflammatory Mediators in Patients With Hemophagocytic Lymphohistiocytosis
Completed
- Conditions
- Interventions
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Swedish Orphan Biovitrum
- Target Recruit Count
- 14
- Registration Number
- NCT06047210
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
An 18-month Low-interventional Study to Assess Joint Health in Haemophilia A and B Patients on Prophylaxis With Efmoroctocog Alfa or Eftrenonacog Alfa
Phase 4
Terminated
- Conditions
- Interventions
- First Posted Date
- 2023-05-12
- Last Posted Date
- 2023-12-20
- Lead Sponsor
- Swedish Orphan Biovitrum
- Target Recruit Count
- 9
- Registration Number
- NCT05856266
- Locations
- 🇸🇮
Study site 147, Ljubljana, Slovenia
🇮🇪Study site 133, Dublin, Ireland
🇨🇿Study site 105, Praha, Czechia
A Study Evaluating Physical Activity and Joint Health in Severe Haemophilia A Patients ≥12 Years Treated Once Weekly With Efanesoctocog Alfa
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Swedish Orphan Biovitrum
- Target Recruit Count
- 93
- Registration Number
- NCT05817812
- Locations
- 🇬🇧
Investigational Site, Oxford, United Kingdom
A Study of Anakinra in Japanese Patients With Still's Disease (SJIA and AOSD)
Phase 3
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-04-14
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Swedish Orphan Biovitrum
- Target Recruit Count
- 15
- Registration Number
- NCT05814159
- Locations
- 🇯🇵
Hyogo Prefectural Kobe Children's Hospital, Kobe, Hyogo, Japan
🇯🇵Yokohama City University Hospital (pediatrics), Yokohama, Kanagawa, Japan
🇯🇵Saitama Prefectural Children's Medical Center, Saitama-shi, Saitama, Japan
A Real World Effectiveness Study of Pegcetacoplan in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Recruiting
- Conditions
- First Posted Date
- 2023-03-20
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Swedish Orphan Biovitrum
- Target Recruit Count
- 200
- Registration Number
- NCT05776472
- Locations
- 🇪🇸
Hospital Lucus Augusti, Lugo, Spain
© Copyright 2024. All Rights Reserved by MedPath